Citations 1
Beyond migraine headache day reduction: Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab (P10-12.008)
Vargas, Bert B., Starling, Amaal J. , Polavieja, Pepa, Katsarava, Zaza , Vincent, Maurice , Lipton, Richard, Nicholson, Robert A. , Viktrup, Lars , Lipton, Richard B.
Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available
